Exin Therapeutics

Headlines · 2

1. 5h
   GPT-6.1 Sol Locates Brain Landmarks in Three Live Mouse Procedures

   Exin Therapeutics reported that OpenAI's GPT-6.1 Sol participated in three consecutive live-mouse brain procedures, using surgeon feedback and prior images, measurements, and corrections to improve anatomical-landmark localization. The team said identification time fell from 169 to 86 seconds and localization error dropped from 0.6 to 0.3 millimeters by the third procedure, while the number of manual corrections fell from four to two. Licensed veterinarians retained control, approved irreversible steps, and supervised every operation; the researchers said three procedures were insufficient to establish stable performance.

   IT之家 AI · 🔥 27
2. Oct 30
   Claude Sonnet 5 Selected Therapy and Controlled Injection in a Live Mouse Experiment

   Biotech startup Exin Therapeutics says an agent running on Anthropic’s Claude Sonnet 5 selected a gene-therapy vector and brain target for an epilepsy mouse, derived injection coordinates from three papers, and controlled a motorized stereotaxic rig to inject 250 nanolitres while monitoring the entry site through a camera. Claude Opus 5.5 and Opus 5 initially refused the live-animal task. Sonnet 5 stopped when it detected a coordinate-calibration error, and researchers fixed the code manually. A licensed veterinarian performed the craniotomy, approved every irreversible step, and held a physical emergency stop. The mouse recovered well, but the results have not been peer-reviewed and no seizure-reduction data has been published.

   MIT科技评论中文 · 🔥 0

Experience and discussion from the community

Share my Exin Therapeutics experienceAsk about Exin Therapeutics